Streptococcus pneumoniae type 33F capsular polysaccharide diphtheria CRM197 protein conjugate antigen

Generic Name
Streptococcus pneumoniae type 33F capsular polysaccharide diphtheria CRM197 protein conjugate antigen
Brand Names
Prevnar 20, Vaxneuvance
Drug Type
Biotech
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
9WP2BC3I04
Background

Streptococcus pneumoniae type 33F capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of Streptococcus pneumoniae serotype 33F individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of Corynebacterium diphtheriae strain C7 (β197). It is contained in the vaccine under the market name Prevnar that contains the saccharides for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F for intramuscular injection. The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.

Associated Conditions
-
Associated Therapies
-

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immunogenicity of AFX3772 Vaccine in Healthy Infants

First Posted Date
2022-06-09
Last Posted Date
2024-12-02
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
472
Registration Number
NCT05412030
Locations
🇺🇸

GSK Investigational Site, South Jordan, Utah, United States

Vaccine Responses in Patients With B Cell Malignancies

First Posted Date
2021-12-28
Last Posted Date
2024-11-27
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
500
Registration Number
NCT05170399
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath